Overview

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
Phase 3 study to examine the relation between antihypertensive effect and baseline factors exploratively, compared to olmesartan medoxomil in patients with essential hypertension.
Phase:
N/A
Details
Lead Sponsor:
Daiichi Sankyo Co., Ltd.
Treatments:
Mineralocorticoid Receptor Antagonists
Olmesartan
Olmesartan Medoxomil